Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression i...
Saved in:
Main Authors: | Véronique Ferret-Sena, Alexandra Maia e Silva, Armando Sena, Inês Cavaleiro, José Vale, Bruno Derudas, Giulia Chinetti-Gbaguidi, Bart Staels |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2016/5716415 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages
by: G. Chinetti-Gbaguidi, et al.
Published: (2016-01-01) -
Peroxisome Proliferator-Activated Receptor and Age-Related Macular Degeneration
by: Chi-Chao Chan, et al.
Published: (2008-01-01) -
Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
by: Jihan Youssef, et al.
Published: (2002-01-01) -
Peroxisome Proliferator-Activated Receptors in Lung Cancer
by: Venkateshwar G. Keshamouni, et al.
Published: (2007-01-01) -
Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
by: Shinji Kume, et al.
Published: (2008-01-01)